Plain-English translation of NCT06293950 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called Wharton Jelly Mesenchymal Stromal Cells () — stem cells taken from umbilical cord tissue — to see if it can help children with autism. Researchers believe this treatment may reduce inflammation and improve how the immune system works in autism. The medication would be given through the vein over several weeks.
Autism involves changes in the brain and problems with the immune system that current treatments don't fully address. This trial exists to see whether stem cell therapy could offer a new way to help children with autism by calming inflammation and supporting better brain function.
You likely qualify if…
You likely don't qualify if…
You would receive three infusions of the stem cell treatment through an IV, with each infusion spaced two weeks apart. Your child would need to attend multiple clinic visits for the infusions and follow-up evaluations. The study will monitor how your child responds over time to see if the treatment helps with autism symptoms.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
Jordan
Sponsor
University of Jordan
Enrollment target
~14 participants
Started
March 2022
Primary completion
June 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
4 Years – 14 Years
Last updated on clinicaltrials.gov in January 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Hanan Jafar, PhD
Cell Therapy Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.